Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007

Journal of Clinical Densitometry

Volumn 11, Issue 2, 2008, Pages 313-324

  Lewiecki, E Michael ^a   Bilezikian, John P ^b   Cooper, Cyrus ^c   Hochberg, Marc C ^d   Luckey, Marjorie M ^e   Maricic, Michael ^f   Miller, Paul D ^g  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e St Barnabas Osteoporosis and Metabolic Bone Disease Center   (United States)

^f Catalina Pointe Arthritis and Rheumatology Specialists   (United States)

^g University of Colorado Health Sciences Center   (United States)

Author keywords

diagnosis; DXA; fracture; osteomalacia; osteonecrosis of the jaw; osteoporosis; reimbursement

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITOMETRY; BONE DENSITY; BONE NECROSIS; CLINICAL PRACTICE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; FRAGILITY FRACTURE; HUMAN; MEDICAL SOCIETY; METABOLIC BONE DISEASE; OSTEOMALACIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; VERTEBRA FRACTURE;

ABSORPTIOMETRY, PHOTON; FRACTURES, BONE; HUMANS; NEW MEXICO; OSTEOPOROSIS;

EID: 42749090024     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2007.12.017     Document Type: Review

References (28)

1. Godfrey K., Walker-Bone K., Robinson S., et al. Neonatal bone mass: influence of parental birthweight, maternal smoking, body composition, and activity during pregnancy. J Bone Miner Res 16 9 (2001) 1694-1703
2. Javaid M.K., Crozier S.R., Harvey N.C., et al. Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet 367 9504 (2006) 36-43
3. Zamora S.A., Rizzoli R., Belli D.C., et al. Vitamin D supplementation during infancy is associated with higher bone mineral mass in prepubertal girls. J Clin Endocrinol Metab 84 12 (1999) 4541-4544
4. Kanis J.A., Oden A., Johnell O., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18 8 (2007) 1033-1046
5. Bouxsein M.L., and Karasik D. Bone geometry and skeletal fragility. Curr Osteoporos Rep 4 2 (2006) 49-56
6. Sanders K.M., Nicholson G.C., Watts J.J., et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?. Bone 38 5 (2006) 694-700
7. Lewiecki E.M., and Laster A.J. Clinical applications of vertebral fracture assessment by dual-energy X-Ray absorptiometry. J Clin Endocrinol Metab 91 11 (2006) 4215-4222
8. Siris E.S., Brenneman S.K., Miller P.D., et al. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older: results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res 19 8 (2004) 1215-1220
9. Barrett-Connor E., Siris E.S., Wehren L.E., et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 20 2 (2005) 185-194
10. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 18 (2007) 1809-1822
11. Canalis E., Giustina A., and Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357 9 (2007) 905-916
12. Black D.M., Greenspan S.L., Ensrud K.E., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349 13 (2003) 1207-1215
13. Finkelstein J.S., Hayes A., Hunzelman J.L., et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349 13 (2003) 1216-1226
14. Deal C., Omizo M., Schwartz E.N., et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20 11 (2005) 1905-1911
15. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 8 (2006) 821-831
16. Keller H., and Kneissel M. SOST is a target gene for PTH in bone. Bone 37 2 (2005) 148-158
17. Tannenbaum C., Clark J., Schwartzman K., et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87 (2003) 4431-4437
18. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 10 (2007) 1479-1489
19. Woo S.B., Hellstein J.W., and Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 10 (2006) 753-761
20. Bilezikian J.P. Osteonecrosis of the jaw-do bisphosphonates pose a risk?. N Engl J Med 355 22 (2006) 2278-2281
21. Holick M.F., Siris E.S., Binkley N., et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90 6 (2005) 3215-3224
22. Reginato A.J., Falasca G.F., Pappu R., et al. Musculoskeletal manifestations of osteomalacia: report of 26 cases and literature review. Semin Arthritis Rheum 28 5 (1999) 287-304
23. Plotnikoff G.A., and Quigley J.M. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 78 12 (2003) 1463-1470
24. Heaney R.P., Dowell M.S., Hale C.A., et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 22 2 (2003) 142-146
25. Drezner M.K. Tumor-induced osteomalacia. Rev Endocr Metab Disord 2 2 (2001) 175-186
26. Garcia C.A., and Spencer R.P. Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med 27 8 (2002) 582-583
27. Javaid M.K., Godfrey K.M., Taylor P., et al. Umbilical venous IGF-1 concentration, neonatal bone mass, and body composition. J Bone Miner Res 19 1 (2004) 56-63
28. Kanis J.A., Johnell O., Oden A., et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12 12 (2001) 989-995